To delineate cellular and molecular mechanisms that underpin drug resistance in KRAS-mutant lung cancer, we modeled adaptive resistance by step-wisely and chronically treating A549 and H358 cells with chemotherapy drug pemetrexed (MTA) whereby resistant populations (A549R and H358R) persisted after the treatment. This evidence concerns the gene KRAS and lung cancer.